The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women.
We studied the effect of treatment with combined oral contraception (COC) with or without spironolactone on the bone mineral density (BMD) of hyperandrogenic women. A group of 22 women (group 1) was treated with ethinylestradiol plus desogestrel for 21 days each month for 12 months, while another group of 21 patients (group 2) was treated with ethinylestradiol and desogestrel for 21 days each month plus spironolactone daily for 12 months. There was no statistically significant difference with respect to mean age, body mass index (BMI) and BMD between the two groups of patients before the treatment. Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), androstenedione, total testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone binding globulin (SHBG), prolactin and estradiol were assessed in both groups and no statistically significant difference was found before treatment. Nor was there any statistically significant difference in bone turnover between the two groups. Statistical analysis was performed using the Student's t test for unpaired data to compare age, BMD and biochemical data, and statistical significance was defined as p < 0.05. The BMD before and after 12 months of treatment showed no statistically significant difference between the patients of group 1 and those of group 2, suggesting that both ethinylestradiol plus desogestrel, and ethinylestradiol and desogestrel plus spironolactone daily for 12 months at the given doses do not affect the BMD of the treated women, while the addition of spironolactone improves the efficacy of hirsutism treatment.
Gregoriou
O
O
Second Department of Obstetrics and Gynecology, Aretaieion Hospital, University of Athens, Greece.
Bakas
P
P
Konidaris
S
S
Papadias
K
K
Mathiopoulos
D
D
Creatsas
G
G
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000097:blood; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use*; D017135:Desogestrel / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000097:blood / Q000503:physiopathology; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D017588:Hyperandrogenism / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D007986:Luteinizing Hormone / Q000097:blood; D015675:Osteocalcin / Q000097:blood; D010710:Phosphates / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use*
D003277:Contraceptives, Oral, Combined; D010710:Phosphates; D015675:Osteocalcin; D013148:Spironolactone; D004997:Ethinyl Estradiol; D017135:Desogestrel; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium